United States-based Akero Therapeutics Inc. (Nasdaq: AKRO), has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for efruxifermin (EFX), an investigational FGF21 analogue, intended for the treatment of non-alcoholic steatohepatitis (NASH), a non-alcoholic fatty liver disease, it was reported on Friday.
The product was granted the designation based on the positive efficacy data recently reported from the company's Phase 2a BALANCED study.
The firm is planning to start a Phase 2b/3 adaptive trial of EFX in biopsy-confirmed NASH patients in the first half of 2021, based on guidance received from the United States Food and Drug Administration (FDA).
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress